VEGF及其受体与肝细胞癌血管生成和抗血管治疗研究进展

Progress of VEGF and its receptors in HCC angiogenesis and antiangiogenesis therapy

肝细胞癌(hepatocellular carcinoma,HCC)发生发展与肿瘤血管生成密切相关,而血管内皮生长因子(vascular endothelial growth factor,VEGF)及其受体能直接或间接参与肝癌血管生成,且具有很强的促进作用,在肝癌的发生、发展及预后中扮演着极其重要的角色。近年来,以VEGF及其受体为靶点的肿瘤抗血管治疗是HCC治疗研究的热点。本文复习近十年相关文献,对VEGF及其受体与HCC肿瘤血管生成和HCC抗血管治疗相关研究进展作简要综述。

The development of hepatocellular carcinoma（HCC） is closely related to angiogenesis of tumors ,vascular endothelial growth factor（VEGF）. Its receptor involves directly or indirectly in angiogenesis of HCC with a strong promoting function and plays very important role on the occurrence, development and prognosis of HCC. In recent years, tumor antiangiogenesis therapy targeted on VEGF and its receptors is a hotspot in HCC treatment. This paper aims to make a review on related research progress of VEGF and its receptors in HCC angiogenesis and antiangiogenesis therapy.